Simparica Trio

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

moksidektin, sarolaner, pyrantel embonate

Available from:

Zoetis Belgium S.A.

ATC code:

QP54AB52

INN (International Name):

sarolaner, moxidectin, pyrantel embonate

Therapeutic group:

Klieb

Therapeutic area:

Antiparasitics

Therapeutic indications:

Għall-klieb b', jew huma f'riskju minn mħallta esterni u interni ' infestazzjonijiet parassitiċi. Il-prodott mediċinali veterinarju huwa esklussivament indikat meta l-użu kontra l-qurdien jew l-briegħed u ħniex gastro-intestinali huwa indikat fl-istess ħin. Il-prodott mediċinali veterinarju jipprovdi wkoll fl-istess ħin l-effikaċja għall-prevenzjoni tad-dudu tal-qalb-mard u l-angiostrongylosis. EctoparasitesFor-trattament ta ' qurdien infestazzjonijiet. Il-prodott mediċinali veterinarju immedjata u persistenti immarka l-qtil tal-attività għall-5 ġimgħat kontra l-Ixodes hexagonus, Ixodes ricinus u Rhipicephalus sanguineus u għal 4 ġimgħat kontra l-Dermacentor reticulatus;Għat-trattament ta ' infestazzjonijiet mill-briegħed (Ctenocephalides felis u Ctenocephalides canis). Il-prodott mediċinali veterinarju immedjata u persistenti joqtol briegħed-attività kontra infestazzjonijiet ġodda għal 5 ġimgħat;Il-prodott mediċinali veterinarju jista 'jintuża bħala parti minn strateġija tat-trattament għall-kontroll ta' dermatite allerġika tal-bergħud (FAD). Gastro-intestinali nematodesFor-trattament ta gastro-intestinali għall-ħniex infezzjonijiet:Toxocara canis adulti immaturi (L5) u adulti;Ancylostoma caninum larva L4, adulti immaturi (L5) u adulti;Toxascaris leonina adulti;Uncinaria stenocephala-adulti. Oħra nematodesFor il-prevenzjoni tal-mard tal-heartworm (Dirofilaria immitis);Għall-prevenzjoni tal-angiostrongylosis billi tnaqqas il-livell ta 'l-infezzjoni bil-adulti immaturi (L5) l-istadji ta' Angiostrogylus vasorum.

Product summary:

Revision: 2

Authorization status:

Awtorizzat

Authorization date:

2019-09-17

Patient Information leaflet

                                17
B. FULJETT TA' TAGĦRIF
18
FULJETT TA’ TAGĦRIF
SIMPARICA TRIO PILLOLI LI JINTMAGĦDU GĦAL KLIEB 1.25–2.5 KG
SIMPARICA TRIO PILLOLI LI JINTMAGĦDU GĦAL KLIEB >2.5–5 KG
SIMPARICA TRIO PILLOLI LI JINTMAGĦDU GĦAL KLIEB >5–10 KG
SIMPARICA TRIO PILLOLI LI JINTMAGĦDU GĦAL KLIEB >10–20 KG
SIMPARICA TRIO PILLOLI LI JINTMAGĦDU GĦAL KLIEB >20–40 KG
SIMPARICA TRIO PILLOLI LI JINTMAGĦDU GĦAL KLIEB >40–60 KG
1.
L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-
TQEGĦID FIS-SUQ U TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦALL-
MANIFATTURA RESPONSABBLI GĦALL-ĦRUĠ TAL-LOTT, JEKK DIFFERENTI
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
IL-BELĠJU
Manifattur responsabbli għall-ħrug tal-lott:
Corden Pharma GmbH
Otto-Hahn-Str., Plankstadt
68723 Baden-Wuerttemberg
IL-ĠERMANJA
jew
Zoetis Manufacturing & Research Spain, S.L.
Ctra. de Camprodón, s/n°
Finca La Riba
Vall de Bianya
Gerona 17813
SPANJA
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Simparica Trio pilloli li jintmagħdu għal klieb 1.25–2.5 kg
Simparica Trio pilloli li jintmagħdu għal klieb >2.5–5 kg
Simparica Trio pilloli li jintmagħdu għal klieb >5–10 kg
Simparica Trio pilloli li jintmagħdu għal klieb >10–20 kg
Simparica Trio pilloli li jintmagħdu għal klieb >20–40 kg
Simparica Trio pilloli li jintmagħdu għal klieb >40–60 kg
Sarolaner, moxidectin, pyrantel (bħala embonate)
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Kull pillola fiha:
SUSTANZA ATTIVA:
Simparica Trio pilloli li jintmagħdu
sarolaner
(mg)
moxidectin
(mg)
pyrantel (bħala
embonate) (mg)
għal klieb 1.25–2.5 kg
3
0.06
12.5
għal klieb >2.5–5 kg
6
0.12
25
għal klieb >5–10 kg
12
0.24
50
19
għal klieb >10–20 kg
24
0.48
100
għal klieb >20–40 kg
48
0.96
200
għal klieb >40–60 kg
72
1.44
300
INGREDJENTI OĦRA:
Butylhydroxytoluene (E321, 0.018%). Koloranti: Sunset Yellow FCF
(E110), Allura Red (E129),
Indigo Carmine (E132).
Pillola lewn kannella fl-aħmar, b
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Simparica Trio pilloli li jintmagħdu għal klieb 1.25–2.5 kg
Simparica Trio pilloli li jintmagħdu għal klieb >2.5–5 kg
Simparica Trio pilloli li jintmagħdu għal klieb >5–10 kg
Simparica Trio pilloli li jintmagħdu għal klieb >10–20 kg
Simparica Trio pilloli li jintmagħdu għal klieb >20–40 kg
Simparica Trio pilloli li jintmagħdu għal klieb >40–60 kg
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull pillola fiha:
SUSTANZA ATTIVA:
Simparica Trio pilloli li jintmagħdu
sarolaner
(mg)
moxidectin
(mg)
pyrantel (bħala
embonate) (mg)
għal klieb 1.25–2.5 kg
3
0.06
12.5
għal klieb >2.5–5 kg
6
0.12
25
għal klieb >5–10 kg
12
0.24
50
għal klieb >10–20 kg
24
0.48
100
għal klieb >20–40 kg
48
0.96
200
għal klieb >40–60 kg
72
1.44
300
INGREDJENTI OĦRA:
Butylhydroxytoluene (E321, 0.018%). Koloranti: Sunset Yellow FCF
(E110), Allura Red (E129),
Indigo Carmine (E132). Għal-lista sħiħa tal-ingredjenti (mhux
attivi), ara s-sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pilloli li jintmagħdu.
Pillola lewn kannella fl-aħmar, b’forma pentagonali bl-ixfra
irrotondjati. Il-pillola hija mnaqqxa bis-
saħħa tas-sarolaner fuq wiċċ wieħed tal-pillola.
4
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Għal klieb b’infestazzjonijiet jew f’riskju ta’
infestazzjonijiet imħallta ta’ parassiti esterni u interni. Il-
prodott mediċinali veterinarju huwa indikat esklussivament meta
l-użu kontra l-qurdien jew il-
briegħed u nematodi gastro-intestinali huwa indikat fl-istess ħin.
Fl-istess ħin, il-prodott mediċinali
veterinarju jipprovdi effikaċja għall-prevenzjoni ta’ mard
tal-heartworm u anġjostronġilożi.
Ettoparassiti
−
Għat-trattament ta’ infestazzjonijiet tal-qurdien. Il-prodott
mediċinali veterinarju għandu attività
immedjata u persistenti li toqtol il-qurdi
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-07-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-07-2021
Public Assessment Report Public Assessment Report Bulgarian 14-10-2019
Patient Information leaflet Patient Information leaflet Spanish 16-07-2021
Public Assessment Report Public Assessment Report Spanish 14-10-2019
Patient Information leaflet Patient Information leaflet Czech 16-07-2021
Public Assessment Report Public Assessment Report Czech 14-10-2019
Patient Information leaflet Patient Information leaflet Danish 16-07-2021
Public Assessment Report Public Assessment Report Danish 14-10-2019
Patient Information leaflet Patient Information leaflet German 16-07-2021
Public Assessment Report Public Assessment Report German 14-10-2019
Patient Information leaflet Patient Information leaflet Estonian 16-07-2021
Public Assessment Report Public Assessment Report Estonian 14-10-2019
Patient Information leaflet Patient Information leaflet Greek 16-07-2021
Public Assessment Report Public Assessment Report Greek 14-10-2019
Patient Information leaflet Patient Information leaflet English 16-07-2021
Public Assessment Report Public Assessment Report English 14-10-2019
Patient Information leaflet Patient Information leaflet French 16-07-2021
Public Assessment Report Public Assessment Report French 14-10-2019
Patient Information leaflet Patient Information leaflet Italian 16-07-2021
Public Assessment Report Public Assessment Report Italian 14-10-2019
Patient Information leaflet Patient Information leaflet Latvian 16-07-2021
Public Assessment Report Public Assessment Report Latvian 14-10-2019
Patient Information leaflet Patient Information leaflet Lithuanian 16-07-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-07-2021
Public Assessment Report Public Assessment Report Lithuanian 14-10-2019
Patient Information leaflet Patient Information leaflet Hungarian 16-07-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 16-07-2021
Public Assessment Report Public Assessment Report Hungarian 14-10-2019
Patient Information leaflet Patient Information leaflet Dutch 16-07-2021
Public Assessment Report Public Assessment Report Dutch 14-10-2019
Patient Information leaflet Patient Information leaflet Polish 16-07-2021
Public Assessment Report Public Assessment Report Polish 14-10-2019
Patient Information leaflet Patient Information leaflet Portuguese 16-07-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 16-07-2021
Public Assessment Report Public Assessment Report Portuguese 14-10-2019
Patient Information leaflet Patient Information leaflet Romanian 16-07-2021
Public Assessment Report Public Assessment Report Romanian 14-10-2019
Patient Information leaflet Patient Information leaflet Slovak 16-07-2021
Public Assessment Report Public Assessment Report Slovak 14-10-2019
Patient Information leaflet Patient Information leaflet Slovenian 16-07-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 16-07-2021
Public Assessment Report Public Assessment Report Slovenian 14-10-2019
Patient Information leaflet Patient Information leaflet Finnish 16-07-2021
Public Assessment Report Public Assessment Report Finnish 14-10-2019
Patient Information leaflet Patient Information leaflet Swedish 16-07-2021
Public Assessment Report Public Assessment Report Swedish 14-10-2019
Patient Information leaflet Patient Information leaflet Norwegian 16-07-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 16-07-2021
Patient Information leaflet Patient Information leaflet Icelandic 16-07-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 16-07-2021
Patient Information leaflet Patient Information leaflet Croatian 16-07-2021
Public Assessment Report Public Assessment Report Croatian 14-10-2019

View documents history